



Human PD-1 Monoclonal Antibody (Research Grade Pembrolizumab Biosimilar)

Recombinant Monoclonal Human IgG1 Clone #FB021

Catalog Number: BIO-013

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human PD-L1/B7-H1 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Pembrolizumab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG4 S228P Clone #FB021
Purification	Protein A/G purified from CHO cell culture supernatant
Immunogen	Human PD-1
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method
Formulation	0.2 µm filtered solution in PBS

APPLICATION

	Recommended Concentration
Flow Cytometry	0.25 µg/10 ⁶ cells

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/ml in sterile 1xPBS
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">• 12 months from the date or receipt, -20 to -70°C as supplied.• 1 month, 2 to 8°C under sterile conditions

BACKGROUND

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. As a PD-1 blocking antibody, Pembrolizumab is used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.